Drug Trial Radar · NCT05162768
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
Last checked: Nov 20, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
Apr 29, 2022
Primary completion
Sep 30, 2024
Study completion Dec 4, 2024
Sponsor
- Lead sponsor
- Stealth BioTherapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary mitochondrial myopathy associated with nuclear DNA mutations (nPMD).
Conditions
- Mitochondrial Myopathies
- Mitochondrial Pathology
- Mitochondrial DNA Mutation
- Mitochondrial Diseases
- Mitochondrial DNA Deletion
- Mitochondrial DNA Depletion
- Mitochondrial Metabolism Defect
- Mitochondrial Complex I Deficiency
Interventions
ElamipretideDrug
60 mg of elamipretide administered as once daily 0.75 mL subcutaneous injections for 48 weeks
PlaceboDrug
Placebo administered as once daily 0.75 mL subcutaneous injections for 48 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Six-minute walk test (6MWT)Time frame: Baseline, Weeks 12, 24, 36, 48, 52 (End of Trial Visit)
Locations
32 sites in 10 countries. Site status is shown where the registry gives one.
University of California, San Diego
San Diego, California
Rare Disease Research, LLC
Atlanta, Georgia
Massachusetts General Hospital
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Columbia University Medical Center College of Physician and Surgeon
New York, New York
Akron Children's Hospital
Akron, Ohio
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
University of Pittsburgh School of Medicine Children's Hospital of Pittsburgh of UPMC Department of Genetics
Pittsburgh, Pennsylvania
UT Health,Center for the Treatment of Pediatric Neurodegenerative Disease
Houston, Texas
Royal North Shore Hospital Neurology
Sydney, New South Wales, Australia
Calvary Health Care Bethlehem
Parkdale, Victoria, Australia
Universitaetsklinikum Carl Gustav Carus Dresden Neurologie
Dresden, Germany
Univ of Tubingen, Hertie Institute for Clinical Brain Research
Tübingen, Germany
Department of Neurology, University Clinics Munich
Munich, Bavaria, Germany
Semmelweis Egyetem Genomikai Medicina es Ritka Betegsegek
Budapest, Hungary
University of Pécs, Department of Neurology Klinikai Kozpont - neurologiai Klinika
Pécs, Hungary
IRCCS Institute of Neorological Sciences of Bologna Bellaria Hospital
Bologna, Italy
Azienda Ospedaliero Universitaria Policlinico G. Martino
Messina, Italy
Istituto Nazionale Neurologico Carlo Besta
Milan, Italy
Azienda Ospedaliero Universitario Pisana, Dipartimento Ambientale di Neuroscienze
Pisa, Italy
University of Brescia, NeMO Clinical Center for Neuromuscular Diseases
Gussago, Brescia, Italy
Istituto di Neurologia, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore
Rome, Lazio, Italy
Radboud University Medical Center
Nijmegen, Netherlands
University of Auckland - Auckland City Hospital, Neurology Department
Auckland, New Zealand
Helse Bergen HF
Bergen, Norway
Hospital de la Sta Creu i Sant Pau
Barcelona, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital la Fe de Valencia
Valencia, Spain
University of Cambridge, Department of Clinical Neurosciences
Cambridge, United Kingdom
Queen Square Centre for Neuromuscular Diseases The National Hospital for Neurology and Neurosurgery
London, United Kingdom
Newcastle upon Tyne Hospitals Freeman Hospital
Newcastle, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.